The functional -374T/A polymorphism of the receptor for advanced glycation end products may modulate Crohn's disease.

The receptor for advanced glycation end products (RAGE) is involved in innate immune mechanisms. Polymorphisms of the RAGE gene have been described as a factor amplifying inflammation in susceptible patients, but the association with Crohn's disease (CD) is not known. The coding RAGE polymorphism G82S (rs2070600) and two promoter polymorphisms, -374T/A (rs1800624) and -429T/C (rs1800625), were studied in two samples from Germany and the United States consisting of 421 and 317 CD patients and 549 and 218 controls, respectively. To test the functional relevance, additional data on serum soluble RAGE (sRAGE), tissue RNA, and protein levels were collected and immunohistochemical stainings of bowel tissue of CD patients and healthy controls as well as models of experimental (dextran sodium sulfate-induced) colitis in RAGE knockout and wild-type mice were performed. The -374T/A RAGE promotor single nucleotide polymorphism (SNP) was negatively associated with CD (odds ratio = 0.708, 95% confidence interval = 0.535-0.938, P = 0.016) and with stenosis (OR = 0.627, P = 0.04) in the German sample. Transmission disequilibrium testing confirmed an undertransmission of the -374A allele. Serum sRAGE levels were higher in patients in complete remission of the -374AA/TA group (1,975 ± 299 pg/ml; -374TT group: 1,310 ± 153 pg/ml SE, P < 0.05) and showed a trend toward decreased levels in CD patients with active disease compared with CD patients in remission. Further in vitro and in vivo studies indicated that an increase of sRAGE ameliorates inflammation. The -429T/C and the G82S polymorphism were not associated with CD. The -374T/A RAGE polymorphism leading to facilitated RAGE gene transcription may to some degree protect from developing a stricturing subphenotype of CD, most likely by increasing levels of sRAGE, which neutralizes proinflammatory mediators.

[1]  Melissa G. Piper,et al.  sRAGE Induces Human Monocyte Survival and Differentiation , 2010, The Journal of Immunology.

[2]  Hiroshi Yamamoto,et al.  Regulation of alternative splicing of the receptor for advanced glycation endproducts (RAGE) through G-rich cis-elements and heterogenous nuclear ribonucleoprotein H. , 2010, Journal of biochemistry.

[3]  大江 和代 Regulation of alternative splicing of the receptor for advanced glycation endproducts (RAGE) through G-rich cis-elements and heterogenous nuclear ribonucleoprotein H , 2010 .

[4]  K. Minematsu,et al.  Low levels of plasma soluble receptor for advanced glycation end products are associated with severe leukoaraiosis in acute stroke patients , 2009, Journal of the Neurological Sciences.

[5]  T. Sweeting,et al.  Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease , 2009, The Journal of Experimental Medicine.

[6]  D. Foell,et al.  The endogenous Toll–like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer , 2009, Journal of leukocyte biology.

[7]  Laurent Abel,et al.  Revisiting Crohn's disease as a primary immunodeficiency of macrophages , 2009, The Journal of experimental medicine.

[8]  Ling Zhang,et al.  Ectodomain shedding of the receptor for advanced glycation end products: a novel therapeutic target for Alzheimer’s disease , 2009, Cellular and Molecular Life Sciences.

[9]  Qi Zhang,et al.  RAGE gene polymorphisms are associated with circulating levels of endogenous secretory RAGE but not with coronary artery disease in Chinese patients with type 2 diabetes mellitus. , 2009, Archives of medical research.

[10]  A. Schmidt,et al.  Alternative splicing of the murine receptor for advanced glycation end‐products (RAGE) gene , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  M. Brown,et al.  Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis , 2009, Arthritis research & therapy.

[12]  B. Spiliotis,et al.  Association Between Serum Levels of the Soluble Receptor (sRAGE) for Advanced Glycation Endproducts (AGEs) and their Receptor (RAGE) in Peripheral Blood Mononuclear Cells of Children with Type 1 Diabetes Mellitus , 2009, Journal of pediatric endocrinology & metabolism : JPEM.

[13]  E. Feskens,et al.  Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels. , 2009, The Journal of clinical endocrinology and metabolism.

[14]  Ze Yang,et al.  Association between the RAGE G82S polymorphism and Alzheimer’s disease , 2009, Journal of Neural Transmission.

[15]  E. Kojro,et al.  Receptor for Advanced Glycation End Products Is Subjected to Protein Ectodomain Shedding by Metalloproteinases* , 2008, Journal of Biological Chemistry.

[16]  P. Saftig,et al.  A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane‐bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10) , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  D. Foell,et al.  Phagocyte‐specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease , 2008, The Journal of pathology.

[18]  M. Mack,et al.  Glucocorticoids induce an activated, anti‐inflammatory monocyte subset in mice that resembles myeloid‐derived suppressor cells , 2008, Journal of leukocyte biology.

[19]  I. Maruyama,et al.  Role of soluble receptor for advanced glycation end products on endotoxin-induced lung injury. , 2008, American journal of respiratory and critical care medicine.

[20]  D. Foell,et al.  Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12. , 2007, Arthritis and rheumatism.

[21]  D. Foell,et al.  Mechanisms of Disease: a 'DAMP' view of inflammatory arthritis , 2007, Nature Clinical Practice Rheumatology.

[22]  T. van der Poll,et al.  Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome , 2007, Critical care medicine.

[23]  U. Broeckel,et al.  DLG5 R30Q Variant Is a Female-Specific Protective Factor in Pediatric Onset Crohn's Disease , 2007, The American Journal of Gastroenterology.

[24]  W. Nacken,et al.  Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. , 2007, Blood.

[25]  C. Costantini,et al.  The −374A allele of the receptor for advanced glycation end products (RAGE) gene promoter is a protective factor against cardiovascular lesions in type 2 diabetes mellitus patients , 2007, Clinical chemistry and laboratory medicine.

[26]  L. Groop,et al.  The −374 T/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic patients , 2006, Diabetologia.

[27]  G. Lichtenstein Sargramostim for Active Crohn's Disease , 2006 .

[28]  D. Foell,et al.  Carboxylated Glycans Mediate Colitis through Activation of NF-κB1 , 2005, The Journal of Immunology.

[29]  P. Gregersen,et al.  The RAGE Gly82Ser polymorphism is not associated with cardiovascular disease in the Framingham offspring study. , 2005, Atherosclerosis.

[30]  K. Tsuneyama,et al.  Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs , 2005, Modern Pathology.

[31]  A. D'Angelo,et al.  Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension , 2005, Journal of hypertension.

[32]  D. Stern,et al.  Understanding RAGE, the receptor for advanced glycation end products , 2005, Journal of Molecular Medicine.

[33]  M. Abreu,et al.  Defects in mucosal immunity leading to Crohn's disease , 2005, Immunological reviews.

[34]  J. Gross,et al.  The -374A allele of the receptor for advanced glycation end products gene is associated with a decreased risk of ischemic heart disease in African-Brazilians with type 2 diabetes. , 2005, Molecular genetics and metabolism.

[35]  A. D'Angelo,et al.  Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Coronary Artery Disease in Nondiabetic Men , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[36]  Andrej Tarkowski,et al.  Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control , 2005, Arthritis research & therapy.

[37]  Kevin J. Tracey,et al.  High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal , 2005, Nature Reviews Immunology.

[38]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[39]  D. Foell,et al.  Carboxylated glycans mediate colitis through activation of NF-kappa B. , 2005, Journal of immunology.

[40]  E. Cario BACTERIAL INTERACTIONS WITH CELLS OF THE INTESTINAL MUCOSA : TOLL-LIKE RECEPTORS AND NOD 2 E Cario , 2005 .

[41]  E. Schleicher,et al.  Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. , 2004, The Journal of clinical investigation.

[42]  Thomas Lengauer,et al.  Genetic variation in DLG5 is associated with inflammatory bowel disease , 2004, Nature Genetics.

[43]  B. Peterlin,et al.  The - 429 T/C and - 374 T/A gene polymorphisms of the receptor of advanced glycation end products gene are not risk factors for diabetic retinopathy in Caucasians with type 2 diabetes. , 2003, Klinische Monatsblatter fur Augenheilkunde.

[44]  G. Bouma,et al.  The immunological and genetic basis of inflammatory bowel disease , 2003, Nature Reviews Immunology.

[45]  D. Foell,et al.  Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease , 2003, Gut.

[46]  M. Perola,et al.  The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. , 2003, Diabetes.

[47]  P. Gregersen,et al.  RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response , 2002, Genes and Immunity.

[48]  Weihong Liu,et al.  A new quantitative method of real time reverse transcription polymerase chain reaction assay based on simulation of polymerase chain reaction kinetics. , 2002, Analytical biochemistry.

[49]  A. Schmidt,et al.  The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. , 2001, The Journal of clinical investigation.

[50]  J. Mužík,et al.  Polymorphisms in the RAGE gene influence susceptibility to diabetes-associated microvascular dermatoses in NIDDM. , 2001, Journal of diabetes and its complications.

[51]  P. Grant,et al.  Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. , 2001, Diabetes.

[52]  M. Neurath,et al.  RAGE Mediates a Novel Proinflammatory Axis A Central Cell Surface Receptor for S100/Calgranulin Polypeptides , 1999, Cell.

[53]  L. Liu,et al.  RAGE Gly82Ser polymorphism in diabetic microangiopathy. , 1999, Diabetes care.

[54]  P. Grant,et al.  Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups. , 1998, Diabetes.

[55]  A. Schmidt,et al.  Characterization and Functional Analysis of the Promoter of RAGE, the Receptor for Advanced Glycation End Products* , 1997, The Journal of Biological Chemistry.